Taro Pharmaceutical Industries Ltd (TARO.N)
9 Dec 2013
|Market Cap (Mil.):||$4,416.55|
|Shares Outstanding (Mil.):||44.79|
BRIEF-Bluemountain Capital Management and Iszo Capital file lawsuit against Taro Pharmaceutical Industries
Nov 21 - BlueMountain Capital Management: * Bluemountain Capital Management and Iszo Capital file lawsuit against Taro
|Ranbaxy Laboratories Limited (RANB.NS)||Rs423.00||-10.60|
|Pfizer Inc. (PFE.N)||$31.29||-0.29|
|Novartis AG (NOVN.VX)||CHF69.15||-0.75|
|Merck & Co., Inc. (MRK.N)||$49.27||-0.29|
|Bayer AG (BAYGn.DE)||€95.76||-1.22|
|Bayer AG (BAYE.F)||--||--|
|GlaxoSmithKline plc (GSK.L)||1,579.50p||-20.00|
|Eli Lilly & Co. (LLY.N)||$50.39||-0.40|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||14,420.00₪||+570.00|
|Bristol-Myers Squibb Co (BMY.N)||$50.90||-0.31|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Taro Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Validea Guru Analysis Report for TARO. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Provider: Ford Investor Services, Inc.
"The Economy Matters" Report for TARO: the economy's impact on TARO's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.